Naoya Fujita

ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 12

Top Venues

NPJ precision oncology

Cancer science

Oncogene

Proceedings of the National Academy of Sciences of the United States of America

Japanese Foundation For Cancer Research

University of Tokyo (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Japanese Foundation For Cancer Research Jan 01 2015

Japan

Center Director :: Cancer Chemotherapy Center

Education History

University of Tokyo - Mar 31 1995

Japan

PHD :: Postgraduate School, Faculty of Pharmaceutical Sciences

Publications

Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. NPJ precision oncology 8 (1) (2024)
Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. NPJ precision oncology 8 (1) (2024)
Ai Takemoto, Satoshi Takagi, Takao Ukaji, Nobuhiko Gyobu, Mamoru Kakino, Miho Takami, Asami Kobayashi, Marie Lebel, Tokuichi Kawaguchi, Minoru Sugawara, Kazue Tsuji-Takayama, Kenji Ichihara, Yuki Funauchi, Keisuke Ae, Seiichi Matsumoto, Yoshiya Sugiura, Kengo Takeuchi, Tetsuo Noda, Ryohei Katayama, Naoya Fujita
Targeting Podoplanin for the Treatment of Osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (12) (2022)
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ precision oncology 6 (1) (2022)
Takuya Sakashita, Noriko Yanagitani, Sumie Koike, Siew-Kee Amanda Low, Satoshi Takagi, Satoko Baba, Kengo Takeuchi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer. Cancer science 113 (11) (2022)
Takao Ukaji, Ai Takemoto, Harumi Shibata, Mamoru Kakino, Satoshi Takagi, Ryohei Katayama, Naoya Fujita
Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. Cancer science 112 (6) (2021)
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Kanada, Yosuke Seto, Tomoko Oh-Hara, Sumie Koike, Ryo Ariyasu, Satoru Kitazono, Hironori Ninomiya, Kengo Takeuchi, Noriko Yanagitani, Satoshi Takagi, Kazuma Kishi, Naoya Fujita, Yasushi Okuno, Makoto Nishio, Ryohei Katayama
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. NPJ precision oncology 5 (1) (2021)
Satoshi Takagi, Yuki Sasaki, Sumie Koike, Ai Takemoto, Yosuke Seto, Mizuki Haraguchi, Takao Ukaji, Tokuichi Kawaguchi, Minoru Sugawara, Masanori Saito, Yuki Funauchi, Keisuke Ae, Seiichi Matsumoto, Naoya Fujita, Ryohei Katayama
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene 40 (36) (2021)
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-Hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature communications 12 (1) (2021)
Ryo Ariyasu, Ken Uchibori, Takaaki Sasaki, Mika Tsukahara, Kazuma Kiyotani, Ryohei Yoshida, Yusuke Ono, Satoru Kitazono, Hironori Ninomiya, Yuichi Ishikawa, Yusuke Mizukami, Noriko Yanagitani, Naoya Fujita, Makoto Nishio, Ryohei Katayama
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. Cancer science 112 (6) (2021)
Kamil Nosol, Ksenija Romane, Rossitza N Irobalieva, Amer Alam, Julia Kowal, Naoya Fujita, Kaspar P Locher
Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. Proceedings of the National Academy of Sciences of the United States of America 117 (42) (2020)
Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, Ryohei Katayama
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. The Journal of experimental medicine 216 (4) (2019)
Mohammad Mahfuz Chowdhury, Mathieu Danoy, Farhana Rahman, Marie Shinohara, Shohei Kaneda, Kiyotaka Shiba, Naoya Fujita, Teruo Fujii, Yasuyuki Sakai
Adhesion of pancreatic cancer cells in a liver-microvasculature mimicking coculture correlates with their propensity to form liver-specific metastasis in vivo. BioMed research international 2014 (2014)

Naoya Fujita.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Naoya Fujita